Onyx Pharmaceuticals commences Appearance 1 den of ONX 0912 spoken proteasome inhibitor as regards cancer
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the origination of a Off 1 research of ONX 0912, an spoken proteasome inhibitor, in patients with advanced refractory or reoccurring unshaky tumors.
"Based on insights gained from our running carfilzomib progress program and ONX 0912′s favorable preclinical value – anti-tumor interest, safe keeping and biodistribution – we think ONX 0912 may acquire the what it takes to flesh out the advantage of proteasome inhibitors in the treatment of cancer," said Ted W. Out of, M.D., Supervisor Shortcoming President and Turning point of Investigate and Unfolding at Onyx Pharmaceuticals. "As an orally-dosed representative, ONX 0912 is designed to stipulate prolonged proteasome defence and relaxed combinability with other orally to hand therapies."
AUTHOR Onyx Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
